Bird & Bird's private equity practice supports sponsors, management teams and institutional investors with buy-out transactions, particularly in regulated and innovation-driven sectors. Co-led by corporate specialists Emmanuelle Porte and Carole Bodin, the team acts in primary and secondary LBOs, MBOs, build-ups, exits and reinvestments, and regularly advises on management incentive packages and shareholder structuring.
Legal 500 Editorial commentary
Accolades
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
- ‘Rigour and pragmatism in handling cases. Knowledge of practices. Negotiation skills.’
Key clients
- ARM
- Sparing Vision
- Infravia Growth
- Caisse des dépôts et consignations
- Enterome
- Coave Therapeutics
- Efeso Consulting Group
- Bpifrance Investissement
- Engie New Ventures
- St-Hubert
- Qwant
- GEI
Work highlights
Advising Bpifrance Large Venture on its participation in the $41m Series A financing round of Bioptimus, a biotech company wishing to develop a specialised generative AI model for biology.
Advising the lead investors Business Opportunities for L'Oreal Development, DTCF, Evonik and Clay Capital in the series A financing round of Abolis Biotechnology, a French company specialising in the development of microbial strains and production methods for industrial use.
Advising BrainEver, a French biotech company specialised in the development of new therapies for patients with age-related neurodegenerative diseases, on its €33m Series B fundraising round to fight Charcot's disease.
Practice head
Emmanuelle Porte; Carole Bodin
Other key lawyers
Gildas Louvel; David Malcoiffe; Bertrand Levy; Félicien Bardsley; Olivier Peronnau; Lionel Berthelet; Sonia Sassi